ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca and Eli Lilly & Co. have agreed to jointly develop and commercialize AstraZeneca’s AZD3293, an oral β-secretase cleaving enzyme (BACE) inhibitor, as a potential treatment for Alzheimer’s disease. Lilly will pay AstraZeneca $50 million up front with additional milestone payments of up to $500 million. The two companies will share the cost of development and commercialization, with Lilly leading clinical development. BACE is an enzyme associated with the development of amyloid-β, a plaque that accumulates in the brain with the progression of Alzheimer’s disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter